Docoh
Loading...
Sign up Log in

GSK Glaxosmithkline

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Company profile

Ticker
GSK
Exchange
NYSE
Website
www.gsk.com/
CEO
Emma Walmsley
Employees
Incorporated
United Kingdom
Location
United Kingdom
Sector
Manufacturing > Medicinal and Botanical Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...
SEC CIK
0001131399
Corporate docs

GSK stock data

(
)

News

Pro users get this 30m faster
Benzinga's Bulls And Bears Of The Week: Alphabet, Coinbase, GE, Quantumscape, Tesla And More
17 Apr 21
Benzinga has examined the prospects for many investor favorite stocks over the past week. The past week's bullish calls included the electric vehicle leader and a prominent IPO. Short sellers were behind some of the bearish calls seen during the week.
BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing
15 Apr 21
GlaxoSmithKline plc (NYSE: GSK) announced the termination of the Phase II and Phase III studies of feladilimab, its ICOS receptor agonist in head and neck cancer. This comes as a disappointment, as the candidate could potentially address a multimillion-dollar market, according to BofA Securities.
Analyzing The Price Action In GlaxoSmithKline Stock Today
15 Apr 21
GlaxoSmithKline's Stock Price And Volume Action GlaxoSmithKline (NYSE:GSK) is currently up 5.41% to a price of $37.99. The stock's current volume for the day is 10.55 million, which is approximately 198.2% of its previous 30-day average volume of 5.32 million.
GSK, Vir Biotechnology Announce European Medicines Agency Review Of Dual-Action Monoclonal Antibody VIR-7831 For Early Treatment of COVID-19
15 Apr 21
Benzinga Pro's Top 5 Stocks To Watch For Thursday, Apr. 15, 2021: DELL, AEO, GSK, UNH, INO
15 Apr 21

Press releases

Pro users get this 30m faster
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
15 Apr 21
LONDON and SAN FRANCISCO, April 15, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (NYSE:GSK) and Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the European Medicines Agency (EMA) has started a review of
GSK Global Head of Vaccine Research and Development Joins Viome To Tackle Chronic Diseases
15 Apr 21
BELLEVUE, Wash., April 15, 2021 /PRNewswire/ -- Viome, a mission-driven systems biology company aiming to help individuals improve their health, today announced the appointment of Dr. Emmanuel Hanon as Global Head of
Thinking about buying stock in Dell Technologies, American Eagle Outfitters, Wrap Technologies, PPD Inc, or GlaxoSmithKline?
15 Apr 21
NEW YORK, April 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DELL, AEO, WRAP, PPD, and GSK.
BioSig Invited to Join Alliance for Artificial Intelligence in Healthcare (AAIH)
9 Apr 21
Flonase teams up with Major League Baseball and World Series champion Cody Bellinger to change the game on allergy season
1 Apr 21

Calendar

12 Mar 21
18 Apr 21

Financial summary

Financial statements Chart GSK financial data
Quarter (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Recent insider trades

GSK insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 Feb 21 Glaxosmithkline Common Stock Buy Aquire P Yes No 18 150,000 2.7M 1,183,663
17 Feb 21 Glaxosmithkline Common Stock Conversion Aquire C Yes No 0 327,852 0 1,033,663
17 Feb 21 Glaxosmithkline Common Stock Conversion Aquire C Yes No 0 247,324 0 705,811
17 Feb 21 Glaxosmithkline Common Stock Conversion Aquire C Yes No 0 458,487 0 458,487
17 Feb 21 Glaxosmithkline Series D Preferred Stock Common Stock Conversion Dispose C Yes No 0 1,737,619 0 0
17 Feb 21 Glaxosmithkline Series C Preferred Stock Common Stock Conversion Dispose C Yes No 0 3,125,000 0 0
17 Feb 21 Glaxosmithkline Series A Preferred Stock Common Stock Conversion Dispose C Yes No 0 7,119,850 0 0
24 Jul 20 Glaxosmithkline Common Stock Buy Aquire P Yes No 2.25 1,260,504 2.84M 4,626,389
24 Jul 20 Glaxosmithkline Warrant Common Stock Buy Aquire P Yes No 0.125 1,260,504 157.56K 1,260,504
21 Jul 20 Glaxosmithkline Common Stock Buy Aquire P Yes No 18 361,111 6.5M 2,248,304
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

GSK institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

12.0% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 784 796 -1.5%
Opened positions 112 76 +47.4%
Closed positions 124 86 +44.2%
Increased positions 234 236 -0.8%
Reduced positions 327 323 +1.2%
13F shares
 Current Prev Q Change
Total value 11.08B 11.15B -0.6%
Total shares 301.11M 296.39M +1.6%
Total puts 2.68M 1.79M +49.2%
Total calls 2.03M 1.95M +4.0%
Total put/call ratio 1.3 0.9 +43.5%
Largest owners
 Shares Value Change
Dodge & Cox 62.94M $2.32B +39.9%
FMR 19.36M $712.49M -2.0%
Capital International Investors 17.62M $648.41M +6.7%
TROW T. Rowe Price 16.55M $608.9M -6.4%
Fisher Asset Management 16.53M $608.18M +1.9%
RY Royal Bank Of Canada 14.71M $541.39M -5.5%
Renaissance Technologies 14.27M $525.19M -22.1%
Hotchkis & Wiley Capital Management 10.36M $381.37M +40.0%
STT State Street 9.51M $354.62M +1.3%
Black Creek Investment Management 7.44M $273.91M +14.8%
Largest transactions
 Shares Bought/sold Change
Dodge & Cox 62.94M +17.94M +39.9%
Renaissance Technologies 14.27M -4.06M -22.1%
Arrowstreet Capital, Limited Partnership 7.26M +3.29M +83.0%
Camber Capital Management 3.5M +3.05M +677.8%
Hotchkis & Wiley Capital Management 10.36M +2.96M +40.0%
American Century Companies 39.74K -2.8M -98.6%
Rockefeller Capital Management 123.59K -2.69M -95.6%
BAC Bank Of America 3.4M -2.27M -40.0%
FHI Federated Hermes 0 -2.25M EXIT
Nuveen Asset Management 2.33M +2.09M +891.0%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Heron Therapeutics • Geovax Labs • Immunogen • Delcath Systems • Adamis Pharmaceuticals • Titan Pharmaceuticals, Inc. • FibroGen • Guided Therapeutics • Mymetics • AIM ImmunoTech
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: adherence, adolescent, adult, Advil, Agency, agile, albuterol, analyze, Annex, antibiotic, attack, attractive, augment, automated, automation, Avolve, ban, Bancroft, behavior, beneficial, Benlysta, Bexsero, Blenrep, bond, Boostrix, carefully, chronic, classic, climate, Cloud, complement, Contac, court, Crispr, CureVac, daprodustat, deployment, Digestive, diligence, disagree, disease, disguised, Dovato, drew, Duvroq, dynamic, EC, EHS, elongated, embracing, empower, Encepur, energy, erode, extremely, feedback, feladilimab, final, Flonase, Flovent, fourth, hacking, harmonization, hospital, IBA, importantly, imposition, indefinite, inequality, Infanrix, inhibitor, intensive, interconnected, interconnectivity, Intercontinental, Juluca, Justice, kidney, learning, legitimacy, lifted, linkage, loan, machine, macroeconomic, medium, Menveo, modern, month, myeloma, nasal, nitrosamine, Nucala, occasionally, OECD, optimize, otilimab, Otrivin, outperform, paediatric, Panadol, panel, PARP, partially, Pediarix, pharmacovigilance, posed, premium, presence, presumption, prioritization, prioritized, pronounced, protectionism, quickly, Rabipur, ransomware, recoverable, refractory, regimen, relapsed, Relenza, repercussion, resilience, rest, resurgence, rooted, Scop, seize, Sensodyne, social, solicit, sophisticated, sought, Specialty, standalone, Sterile, streamline, strength, summarize, summarized, synergy, temporarily, Theraflu, timeline, Tivicay, traditional, Transderm, Trelegy, tuition, turn, twelve, undermine, understood, unfavorable, unique, unknown, unregulated, urgent, variable, Ventolin, vir, water, weak, week, worsened, Zejula
Removed: aid, analyse, andBoostrix, andTivicay, asserted, background, Beecham, commercialisation, Cooperation, coverage, cybersecurity, defendant, determination, Ebola, Ellipta, erosion, evident, frequently, GDPR, geographical, Glaxo, inappropriate, incremental, inherently, inInternal, Insufficient, integral, intent, interaction, labelling, measurable, media, merged, method, misuse, newer, November, ofBenlysta, ofSeretide, older, outbreak, outsourced, phasing, predecessor, preventing, procured, publishing, punitive, pursuit, remeasurement, replacing, side, SmithKline, solution, spread, storm, summarise, sustainability, therapeutic, Theravance, unanticipated, unauthorised, unpredictable, Wellcome, widely
From filing 20-F 2020 FY

Financial reports

View all
20-F
2020 FY
Annual report (foreign)
12 Mar 21
20-F
2019 FY
Annual report (foreign)
6 Mar 20
20-F
2018 FY
Annual report (foreign)
15 Mar 19
20-F/A
2017 FY
Annual report (foreign) (amended)
19 Mar 18
20-F
2017 FY
Annual report (foreign)
15 Mar 18
20-F
2016 FY
Annual report (foreign)
16 Mar 17
20-F
2015 FY
Annual report (foreign)
17 Mar 16
20-F
2014 FY
Annual report (foreign)
26 Feb 15
20-F
2013 FY
Annual report (foreign)
27 Feb 14
20-F
2012 FY
Annual report (foreign)
7 Mar 13

Current reports

View all
6-K
Director/pdmr Shareholding
16 Apr 21
6-K
Director/pdmr Shareholding
15 Apr 21
6-K
Director/pdmr Shareholding
15 Apr 21
6-K
Director/pdmr Shareholding
14 Apr 21
6-K
Director/pdmr Shareholding
14 Apr 21
6-K
Director/pdmr Shareholding
12 Apr 21
6-K
Director/pdmr Shareholding
12 Apr 21
6-K
Director/pdmr Shareholding
9 Apr 21
6-K
Director/pdmr Shareholding
9 Apr 21
6-K
Directorate Change
6 Apr 21

Registration and prospectus

View all
F-3ASR
Automatic shelf registration (foreign)
26 Mar 21
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
15 Mar 21
25-NSE
Exchange delisting
13 Oct 20
8-A12B
Registration of securities on exchange
1 Oct 20
424B2
Prospectus for primary offering
30 Sep 20
FWP
Free writing prospectus
28 Sep 20
FWP
Free writing prospectus
28 Sep 20
424B2
Prospectus for primary offering
28 Sep 20
S-8
Registration of securities for employees
20 Dec 19
F-6
Registration for ADRs (foreign)
19 Jul 19

Proxies

No filings

Other

View all
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
12 Mar 21
SD
Conflict minerals disclosure
29 May 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 20
EFFECT
Notice of effectiveness
30 Jul 19
SD
Conflict minerals disclosure
31 May 19
CT ORDER
Confidential treatment order
2 May 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
15 Mar 19
SD
Conflict minerals disclosure
30 May 18
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
15 Mar 18
SD
Conflict minerals disclosure
30 May 17

Ownership

View all
SC 13D/A
BICYCLE THERAPEUTICS / GLAXOSMITHKLINE ownership change
16 Apr 21
SC 13D/A
Pandion Therapeutics / GLAXOSMITHKLINE ownership change
8 Apr 21
4
Change in insider ownership
19 Feb 21
SC 13G/A
GENOCEA BIOSCIENCES / GLAXOSMITHKLINE ownership change
12 Feb 21
SC 13G/A
Progyny / GLAXOSMITHKLINE ownership change
12 Feb 21
3
Initial statement of insider ownership
11 Feb 21
SC 13D/A
Innoviva / GLAXOSMITHKLINE ownership change
11 Feb 21
SC 13G/A
GLAXOSMITHKLINE / BlackRock ownership change
29 Jan 21
SC 13D/A
Spero Therapeutics / GLAXOSMITHKLINE ownership change
7 Dec 20
SC 13D/A
BICYCLE THERAPEUTICS / GLAXOSMITHKLINE ownership change
7 Dec 20

Transcripts

2020 Q3
Earnings call transcript
28 Oct 20

Reddit threads

View all